top of page

NEUROFIBROMATOSIS
CURRENTLY ENROLLING TRIALS

nflection-logo.png

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2
Dose-Response Study to Determine Safety and Effectiveness of Two
Concentrations of NFX-179 Gel in Subjects with Cutaneous Neurofibromas

Open for participants age 18 and older with a documented clinical diagnosis of Neurofibromatosis Type 1 (NF1).

 

Requirements:

  • At least 10 cutaneous neurofibromas (cNF) currently present with at least 2 on the face.

 

Further inclusion/exclusion criteria apply. If you think you may qualify, please contact us.

Don't qualify for any of our trials?

UPCOMING CLINICAL TRIALS

We begin new trials often. If you do not qualify for our current studies, please leave your information, and we'll keep you updated of any upcoming trials that may be right for you.

Note: If you are under the age of 18, please have your parent/guardian call us directly at 847-663-8530.

Thanks for submitting!

©2023 by Derm CTU. Find us on:

  • Facebook
bottom of page